Next, we wanted to assess the potential of combining SM08502 with olaparib to inhibit tumor progression in an established BRCA2-mutated olaparib-resistant PDX model, PDX-GTFB1016-OR, in immunodeficient mice (22, 33). Here, BRCA2 is linked to neoplasm.